Skip to search formSkip to main contentSkip to account menu

U 100766

Known as: PNU-100766, PNU100766, PNU 100766 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2003
Review
2003
Each antimicrobial agent developed for clinical use during the past 60 years has ultimately encountered problems with the… 
Highly Cited
2002
Highly Cited
2002
Gram-positive (GP) cocci, mainly methicillin-resistant staphylococci, are the most frequent pathogens involved in central nervous… 
Highly Cited
2001
Highly Cited
2001
Linezolid, the first oxazolidinone, is active against gram-positive bacteria, including multidrug-resistant strains. This… 
Highly Cited
2000
Highly Cited
2000
ABSTRACT This randomized, double-blind, multicenter trial compared the efficacy and safety of linezolid, an oxazolidinone, with… 
Highly Cited
1998
Highly Cited
1998
The in-vitro activity of linezolid, a novel oxazolidinone, was investigated in comparison with those of amoxycillin, cefuroxime… 
Highly Cited
1998
Highly Cited
1998
ABSTRACT The activities of the oxazolidinone antibacterial agents eperezolid (PNU-100592) and linezolid (PNU-100766) were… 
Highly Cited
1996
Highly Cited
1996
Bacterial resistance development has become a very serious clinical problem for many classes of antibiotics. The 3-aryl-2… 
Highly Cited
1996
Highly Cited
1996
Oxazolidinones make up a relatively new class of antimicrobial agents which possess a unique mechanism of bacterial protein… 
Highly Cited
1996
Highly Cited
1996
The Upjohn oxazolidinones, U-100592 and U-100766, are orally bioavailable synthetic antimicrobial agents with spectra of activity… 
Highly Cited
1996
Highly Cited
1996
The new oxazolidinone antimicrobial agents U100592 and U100766 demonstrated good in vitro inhibitory activity against clinical…